Vaxart (NASDAQ:VXRT) versus Black Diamond Therapeutics (NASDAQ:BDTX) Head-To-Head Comparison

Black Diamond Therapeutics (NASDAQ:BDTXGet Free Report) and Vaxart (NASDAQ:VXRTGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Black Diamond Therapeutics and Vaxart, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Black Diamond Therapeutics 0 0 4 0 3.00
Vaxart 0 0 2 0 3.00

Black Diamond Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 436.33%. Vaxart has a consensus price target of $3.00, indicating a potential upside of 289.66%. Given Black Diamond Therapeutics’ higher possible upside, equities analysts clearly believe Black Diamond Therapeutics is more favorable than Vaxart.

Valuation and Earnings

This table compares Black Diamond Therapeutics and Vaxart”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Black Diamond Therapeutics N/A N/A -$82.44 million ($1.50) -1.93
Vaxart $7.38 million 18.51 -$82.46 million ($0.46) -1.67

Black Diamond Therapeutics has higher earnings, but lower revenue than Vaxart. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Black Diamond Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Profitability

This table compares Black Diamond Therapeutics and Vaxart’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Black Diamond Therapeutics N/A -69.08% -51.68%
Vaxart -543.21% -114.19% -75.68%

Institutional and Insider Ownership

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 18.1% of Vaxart shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 2.6% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Black Diamond Therapeutics beats Vaxart on 9 of the 12 factors compared between the two stocks.

About Black Diamond Therapeutics

(Get Free Report)

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

About Vaxart

(Get Free Report)

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.